Developing real-world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond

被引：2
|
作者：
Huo, Teh-Ia [1 ,3 ]
Liao, Jia-, I [2 ,4 ]
Ho, Shu-Yein [4 ,5 ]
机构：
[1] Taipei Vet Gen Hosp, Dept Med Res, 201, Sec 2, Shipai Rd, Taipei 11217, Taiwan
[2] Taipei Vet Gen Hosp, Dept Med, Taipei, Taiwan
[3] Natl Yang Ming Chiao Tung Univ, Inst Pharmacol, Taipei, Taiwan
[4] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan
[5] Min Sheng Gen Hosp, Div Gastroenterol & Hepatol, Taoyuan, Taiwan
来源：
HEPATOLOGY INTERNATIONAL | 2023年 / 17卷 / 02期
关键词：
SCORE;
D O I：
10.1007/s12072-022-10467-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：512 / 513
页数：2
相关论文
共 50 条
  • [1] Developing real-world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond
    Teh-Ia Huo
    Jia-I Liao
    Shu-Yein Ho
    Hepatology International, 2023, 17 : 512 - 513
  • [2] Reply to: "developing real-world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond"
    Hatanaka, Takeshi
    Kakizaki, Satoru
    Hiraoka, Atsushi
    Toyoda, Hidenori
    Kumada, Takashi
    HEPATOLOGY INTERNATIONAL, 2023, 17 (05) : 1320 - 1321
  • [3] Reply to: “developing real‑world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond”
    Takeshi Hatanaka
    Satoru Kakizaki
    Atsushi Hiraoka
    Hidenori Toyoda
    Takashi Kumada
    Hepatology International, 2023, 17 : 1320 - 1321
  • [4] Real-world data on nivolumab treatment in Asian patients with advanced hepatocellular carcinoma
    Yoon, S. E.
    Hur, J. Y.
    Lee, K. K.
    Lee, S. J.
    Lee, J.
    Paik, S. W.
    Lim, H. Y.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] Multicenter, real-world experience with lenvatinib for patients with advanced hepatocellular carcinoma in Japan
    Sho, Takuya
    Suda, Goki
    Ogawa, Koji
    Nakai, Masato
    Morikawa, Kenichi
    Sakamoto., Naoya
    JOURNAL OF HEPATOLOGY, 2020, 73 : S909 - S909
  • [6] Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
    Yen-Hao Chen
    Ching-Hua Tsai
    Yen-Yang Chen
    Chih-Chi Wang
    Jing-Houng Wang
    Chao-Hung Hung
    Yuan-Hung Kuo
    BMC Cancer, 23
  • [7] Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
    Chen, Yen-Hao
    Tsai, Ching-Hua
    Chen, Yen-Yang
    Wang, Chih-Chi
    Wang, Jing-Houng
    Hung, Chao-Hung
    Kuo, Yuan-Hung
    BMC CANCER, 2023, 23 (01)
  • [8] Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting
    Sho, Takuya
    Suda, Goki
    Ogawa, Koji
    Kimura, Megumi
    Shimazaki, Tomoe
    Maehara, Osamu
    Shigesawa, Taku
    Suzuki, Kazuharu
    Nakamura, Akihisa
    Ohara, Masatsugu
    Umemura, Machiko
    Kawagishi, Naoki
    Natsuizaka, Mitsuteru
    Nakai, Masato
    Morikawa, Kenichi
    Furuya, Ken
    Baba, Masaru
    Yamamoto, Yoshiya
    Kobayashi, Tomoe
    Meguro, Takashi
    Saga, Akiyoshi
    Miyagishima, Takuto
    Yokoo, Hideki
    Kamiyama, Toshiya
    Taketomi, Akinobu
    Sakamoto, Naoya
    JGH OPEN, 2020, 4 (01): : 54 - 60
  • [9] Real-world experience of lenvatinib-based therapy in patients with advanced hepatocellular carcinoma
    Wang, Hung-Wei
    Lai, Hsueh-Chou
    Su, Wen-Pang
    Kao, Jung-Ta
    Hsu, Wei-Fan
    Chen, Hung-Yao
    Chang, Che-Wei
    Huang, Guan-Tarn
    Peng, Cheng-Yuan
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (05)
  • [10] Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting
    Sho, Takuya
    Suda, Goki
    Ogawa, Koji
    Nakai, Masato
    Morikawa, Kenichi
    Sakamoto, Naoya
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E621 - E621
12345